Anzeige
Mehr »
Freitag, 27.06.2025 - Börsentäglich über 12.000 News
Ein echter Gamechanger: Diese News kann den Grundstein für eine Neubewertung der Rock-Tech-Aktie legen!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 858523 | ISIN: JP3256000005 | Ticker-Symbol: KY4
Tradegate
25.06.25 | 21:17
14,500 Euro
-1,36 % -0,200
Branche
Pharma
Aktienmarkt
NIKKEI-225
1-Jahres-Chart
KYOWA KIRIN CO LTD Chart 1 Jahr
5-Tage-Chart
KYOWA KIRIN CO LTD 5-Tage-Chart
RealtimeGeldBriefZeit
14,30014,60008:09
14,30014,70008:00

Aktuelle News zur KYOWA KIRIN Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
12.06.Kura Oncology, Inc.: Kura Oncology and Kyowa Kirin Report Positive Updated Combination Data for Ziftomenib in Newly Diagnosed AML at 2025 European Hematology Association Congress231- Encouraging clinical activity with deep responses demonstrated in the KOMET-007 trial with the combination of 600 mg ziftomenib with 7+3 in newly diagnosed patients with NPM1-m and KMT2A-r AML -...
► Artikel lesen
03.06.Kura Oncology, Inc.: Kura Oncology and Kyowa Kirin Report Positive Pivotal Ziftomenib Monotherapy Data at 2025 ASCO Annual Meeting130- CR/CRh rate of 23% in pivotal Ph 2 cohort of R/R NPM1-m AML patients - - Consistent efficacy with comparable CR/CRh rates and clinically meaningful MRD-negative responses across pre-specified subgroups...
► Artikel lesen
02.06.FDA Grants Priority Review for Kura Oncology, Inc. (KURA) and Kyowa Kirin's Ziftomenib4
02.06.Kura Oncology, Inc.: Kura Oncology and Kyowa Kirin Announce FDA Acceptance and Priority Review of New Drug Application for Ziftomenib in Adults with Relapsed or Refractory NPM1-Mutant AML112- New Drug Application based on positive results from the Phase 2 KOMET-001 trial - - FDA assigns a Prescription Drug User Fee Act (PDUFA) target action date of November 30, 2025 - - Potential first...
► Artikel lesen
23.05.Kura Oncology, Inc. (KURA) and Kyowa Kirin to Present Promising Ziftomenib Data at ASCO 20257
KYOWA KIRIN Aktie jetzt für 0€ handeln
22.05.Kura Oncology, Inc.: Kura Oncology and Kyowa Kirin Announce Pivotal Monotherapy Data for Ziftomenib in Oral Presentation at the 2025 ASCO Annual Meeting143- Results from KOMET-001 registration-directed trial of ziftomenib in R/R NPM1-m AML patients selected for oral presentation on Monday, June 2nd - - Encore presentation planned at EHA 2025 Congress...
► Artikel lesen
14.05.Kura Oncology, Inc.: Kura Oncology and Kyowa Kirin Announce Combination Data for Ziftomenib in Oral Presentation at the 2025 European Hematology Association (EHA) Congress213- Ziftomenib combined with 7+3 in 1L NPM1-m or KMT2A-r AML patients selected for oral presentation on Thursday, June 12th - - Updated dataset to be presented in oral presentation at EHA2025 Congress...
► Artikel lesen
18.04.Fierce Pharma Asia-The latest on Trump's tariffs; Leqembi's EU approval; Kyowa Kirin's biologics plant4
14.04.Kyowa Kirin constructs drug manufacturing facility in Japan2
11.04.As work on massive US plant continues, Kyowa Kirin wraps up construction of $118M biologics plant in Japan2
08.04.Kura Oncology, Inc.: Kura Oncology and Kyowa Kirin Announce Submission of New Drug Application for Ziftomenib to FDA235SAN DIEGO and TOKYO, April 08, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA, "Kura"), and Kyowa Kirin Co., Ltd. (TSE: 4151, "Kyowa Kirin"), today announced Kura submitted a New Drug...
► Artikel lesen
12.03.Amgen/Kyowa Kirin share promising phase 3 results for rocatinlimab in atopic dermatitis22
10.03.Amgen And Kyowa Kirin's Rocatinlimab Reduces Eczema Severity In Phase 3 Study7
08.03.Amgen And Kyowa Kirin Provide Top-line Results From Rocatinlimab Phase 3 Ignite Study In Adults With Moderate To Severe Atopic Dermatitis426Ongoing Studies are Evaluating Long-Term Maintenance and Durability THOUSAND OAKS, Calif., and TOKYO, March 8, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and Kyowa Kirin Co., Ltd. (Kyowa...
► Artikel lesen
06.02.Kyowa Kirin GAAP EPS of ¥113.06, revenue of ¥495.56B5
05.02.Kura Oncology, Inc.: Kura Oncology and Kyowa Kirin Announce Positive Ziftomenib Monotherapy Registrational Trial and Positive FDA Feedback for Upcoming Frontline Combination Trial Designs187- KOMET-001 registrational trial in R/R NPM1-m AML achieved primary CR/CRh endpoint; topline data submitted for presentation at an upcoming medical meeting - - NDA submission for ziftomenib on track...
► Artikel lesen
04.02.Bristol Myers Squibb, Kyowa Kirin layoffs hit 119 in New Jersey amid separate restructuring campaigns2
30.01.Kyowa Kirin International: Kyowa Kirin and Swixx BioPharma announce expansion of access to POTELIGEO (mogamulizumab) for adults living with mycosis fungoides or Sézary syndrome in Central and Eastern Europe504Second- and third-line treatment for adults with mycosis fungoides or Sézary syndrome reimbursed by Croatia's National Health Insurance Fund (NHIF), effective as of 15th November 2024. ...
► Artikel lesen
27.12.24Dividendenbekanntmachungen (27.12.2024)16.916 Unternehmen  ISIN-Code  Dividende (Währung)  Dividende (EUR)  ADWAYS INC  JP3121970002  3 JPY  0,0182 EUR  AGC INC  JP3112000009  105 JPY  0,6373 EUR  ALERUS FINANCIAL CORPORATION  US01446U1034  0...
► Artikel lesen
10.12.24Cimeio Therapeutics Announces Partnership with Kyowa Kirin to Develop Novel Cell Therapies840-- Collaboration leverages Cimeio's novel epitope shielding and immunotherapy discovery expertise -- -- Cimeio is eligible to receive an upfront payment and two years of research funding, as...
► Artikel lesen
Weiter >>
31 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1